BOSTON BIOMEDICA INC
10-Q, EX-27, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: BOSTON BIOMEDICA INC, 10-Q, 2000-11-14
Next: BIOPOOL INTERNATIONAL INC, 10QSB, 2000-11-14



<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                                  9-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-END>                                   SEP-30-2000
<CASH>                                         2,525,402
<SECURITIES>                                   0
<RECEIVABLES>                                  6,225,992
<ALLOWANCES>                                   (848,655)
<INVENTORY>                                    7,273,526
<CURRENT-ASSETS>                               15,549,148
<PP&E>                                         14,443,559
<DEPRECIATION>                                 (6,240,431)
<TOTAL-ASSETS>                                 25,082,382
<CURRENT-LIABILITIES>                          10,387,930
<BONDS>                                        0
                          0
                                    0
<COMMON>                                       56,467
<OTHER-SE>                                     9,213,745
<TOTAL-LIABILITY-AND-EQUITY>                   25,082,382
<SALES>                                        8,780,907
<TOTAL-REVENUES>                               21,085,866
<CGS>                                          4,570,407
<TOTAL-COSTS>                                  13,961,273
<OTHER-EXPENSES>                               10,932,723
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             794,442
<INCOME-PRETAX>                                (4,593,475)
<INCOME-TAX>                                   (1,135,267)
<INCOME-CONTINUING>                            (5,728,742)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (5,728,742)
<EPS-BASIC>                                    (1.02)
<EPS-DILUTED>                                  (1.02)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission